Last updated on January 2020

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

Brief description of study

The main purpose of this study is to evaluate safety and efficacy in participants treated with concomitant chemoradiation therapy (cCRT) plus M7824 followed by M7824 compared to cCRT plus placebo followed by durvalumab.

Clinical Study Identifier: NCT03840902

Find a site near you

Start Over

FirstHealth of the Carolinas, Inc.

Pinehurst, NC United States
  Connect »